91 related articles for article (PubMed ID: 21962339)
1. Novel head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells.
Duhoux FP; Ameye G; Lambert C; Herman M; Iossifidis S; Constantinescu SN; Libouton JM; Demoulin JB; Poirel HA
Leuk Res; 2012 Jan; 36(1):e27-30. PubMed ID: 21962339
[No Abstract] [Full Text] [Related]
2. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
[TBL] [Abstract][Full Text] [Related]
3. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
4. Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis.
Au WY; Fung A; Lie AK; Lam KY; Lam CC; Kwong YL
Ann Hematol; 2007 Feb; 86(2):145-7. PubMed ID: 17111143
[No Abstract] [Full Text] [Related]
5. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.
Ziakas PD
Haematologica; 2008 Sep; 93(9):1412-4. PubMed ID: 18641024
[No Abstract] [Full Text] [Related]
6. JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report.
Yhim HY; Kim HS; Sohn JY; Song MJ; Lee NR; Song EK; Choi SI; Yim CY; Kwak JY
Cancer Genet Cytogenet; 2010 Apr; 198(2):162-5. PubMed ID: 20362232
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of JAK2 (V617F) mutant allele burden.
Passamonti F; Rumi E
Haematologica; 2009 Jan; 94(1):7-10. PubMed ID: 19118374
[TBL] [Abstract][Full Text] [Related]
8. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.
Ohyashiki K; Kiguchi T; Ito Y; Fujimoto H; Gotoh A; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Int J Hematol; 2008 May; 87(4):446-448. PubMed ID: 18409076
[No Abstract] [Full Text] [Related]
9. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia.
Moreno MJ; Lozano ML; Roldán V; Bellosillo B; García-Barberá N; Rivera J; Navarro-Núñez L; Besses C; Vicente V; Martínez C
Ann Hematol; 2008 Sep; 87(9):763-5. PubMed ID: 18365193
[No Abstract] [Full Text] [Related]
11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the progression of JAK2 V617F positive myeloproliferative neoplasms by single-nucleotide polymorphism array does not reveal a strong chromosomal instability.
Knoops L; Amyere M; Selleslag D; van Hees J; Girardot M; Michaux L
Cancer Genet Cytogenet; 2009 Jul; 192(2):102-4. PubMed ID: 19596266
[No Abstract] [Full Text] [Related]
13. JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
Hsiao HH; Liu YC; Tsai HJ; Lee CP; Hsu JF; Lin SF
Leuk Lymphoma; 2011 Mar; 52(3):478-82. PubMed ID: 21281225
[TBL] [Abstract][Full Text] [Related]
14. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
15. MPL W515L mutation in pediatric essential thrombocythemia.
Farruggia P; D'Angelo P; La Rosa M; Scibetta N; Santangelo G; Lo Bello A; Duner E; Randi ML; Putti MC; Santoro A
Pediatr Blood Cancer; 2013 Aug; 60(8):E52-4. PubMed ID: 23441089
[TBL] [Abstract][Full Text] [Related]
16. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis.
Lim KH; Chang YC; Gon-Shen Chen C; Lin HC; Wang WT; Chiang YH; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Kuo YY; Chou WC
Blood Cancer J; 2015 Mar; 5(3):e295. PubMed ID: 25794131
[No Abstract] [Full Text] [Related]
17. Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT2A amplification as a homogenously staining region.
Wang HY; Tanaka TN; Dell'Aquila M
Br J Haematol; 2019 Aug; 186(4):509. PubMed ID: 31134617
[No Abstract] [Full Text] [Related]
18. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
19. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
Sultan S; Irfan SM
Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
[TBL] [Abstract][Full Text] [Related]
20. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.
Dahabreh IJ; Zoi K; Giannouli S; Zoi C; Loukopoulos D; Voulgarelis M
Leuk Res; 2009 Jan; 33(1):67-73. PubMed ID: 18632151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
